Is St. John’s wort appropriate for treating mild‑to‑moderate depression in an otherwise healthy adult, and what dosage and contraindications apply?

St. John's Wort for Mild-to-Moderate Depression

St. John's wort is a reasonable treatment option for mild-to-moderate depression in otherwise healthy adults, with efficacy comparable to standard antidepressants but significantly fewer side effects and lower discontinuation rates. 1

Efficacy Evidence

Meta-analyses of 9 trials involving 1,513 participants demonstrated that St. John's wort produces similar response rates to second-generation antidepressants (54% vs. 52%) after 6-12 weeks of treatment 1. Remission rates were also comparable (36% vs. 30%) across 5 trials with 768 participants 1. The American College of Physicians guidelines recognize St. John's wort as an acceptable complementary and alternative medicine option for major depressive disorder 2.

Importantly, patients treated with St. John's wort had significantly lower discontinuation rates due to adverse events (4% vs. 7%) compared to those on antidepressants 1. This represents a clinically meaningful advantage in real-world tolerability.

Dosing Recommendations

Use standardized extracts containing 0.12% to 0.28% hypericin at dosages of 300-900 mg daily, typically divided into three doses (e.g., 300 mg three times daily) 1. The hyperforin content matters—extracts with 5% hyperforin show superior efficacy compared to 0.5% hyperforin preparations 3. Treatment duration should be at least 6-12 weeks to assess response.

Critical Contraindications and Drug Interactions

Absolute Contraindications:

• Concurrent use with any monoamine oxidase inhibitors (MAOIs) - risk of serotonin syndrome 4
• Concurrent use with SSRIs, SNRIs, or other serotonergic medications - risk of serotonin syndrome 4, 5
• Patients taking immunosuppressants (cyclosporine, tacrolimus) - risk of organ rejection 6, 7
• Patients taking HIV protease inhibitors (indinavir, nevirapine) - therapeutic failure 6, 7

Major Drug Interactions via CYP3A4 Induction:

St. John's wort induces cytochrome P450 enzymes (particularly CYP3A4) and P-glycoprotein, reducing plasma concentrations of numerous medications 6, 8, 7:

• Oral contraceptives - risk of unintended pregnancy
• Warfarin/anticoagulants - risk of thrombosis
• Digoxin - reduced efficacy
• Chemotherapy agents (irinotecan) - treatment failure
• Theophylline - reduced bronchodilation
• Simvastatin and other statins - reduced cholesterol control
• Methadone - withdrawal symptoms

Relative Contraindications:

• Severe depression (insufficient evidence) 1, 6
• Pregnancy and breastfeeding (insufficient safety data)
• History of photosensitivity disorders (rare risk of cutaneous photosensitization) 6

Clinical Caveats

A critical limitation: Most trials compared St. John's wort against moderate- or low-dose antidepressants, not fully optimized doses 1. This may overestimate St. John's wort's relative efficacy. However, the tolerability advantage remains robust.

Serotonin syndrome warning: When combined with serotonergic drugs, symptoms can develop within 24-48 hours and include mental status changes, neuromuscular hyperactivity (tremors, clonus), and autonomic instability (hypertension, tachycardia, diaphoresis) 4. This is a medical emergency requiring immediate discontinuation and supportive care.

Patient expectancy effects: One reanalysis found that patients' beliefs about treatment assignment were more strongly associated with outcomes than actual treatment received 1. This underscores the importance of discussing treatment rationale and setting appropriate expectations.

Practical Implementation Algorithm

1. Screen for drug interactions: Review all current medications, supplements, and over-the-counter products
2. Confirm diagnosis: Mild-to-moderate depression (not severe, not bipolar)
3. Obtain informed consent: Discuss drug interaction risks, particularly with oral contraceptives
4. Start dosing: 300 mg three times daily of standardized extract (0.12-0.28% hypericin, preferably 5% hyperforin)
5. Monitor response: Assess at 2,4,6, and 8 weeks using standardized scales
6. Duration: Continue for at least 4 months after remission for first episode 5

Do not combine St. John's wort with prescription antidepressants 1. No evidence supports combination therapy, and the risk of serotonin syndrome is substantial.

For patients on multiple medications or with complex medical histories, standard antidepressants with predictable pharmacokinetics may be safer despite higher side effect rates. For otherwise healthy adults with mild-to-moderate depression taking minimal medications, St. John's wort represents an evidence-based first-line option with favorable tolerability 2, 9.